Thanks Gary. Poking around tonight I came across this which you probably already have. I'd like to do some learning on Histamines actually. I don't know much about
them at all other than the obvious allergic reaction side of things. Wiki says diamine oxidase may play a role in other tissues - so I'm going to look it up and see if I can find anything in my text books. I don't recall ever reading/learning about
it.
If we really are low then it really might make sense to add this to the supplement side of things. I'm curious if they have measured this in IBS now actually... Specially if one has barrier defects like tissue damage/scarring and so on.
-------
Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability:
onlinelibrary.wiley.com/doi/10.1002/ibd.21588/fullDISCUSSION
This study first demonstrates that serum DAO activity is significantly lower in patients with CD and UC regardless of the level of disease activity. Of note, in patients with UC in whom small intestinal inflammation was not involved, serum DAO activity was significantly lower than that in healthy controls. These findings strongly indicate that small intestinal permeability is strongly involved in the pathophysiology of not only CD but also UC.
A recent animal study showed that reducing small intestinal permeability using AT-1001 (a zonulin peptide inhibitor) attenuates colonic inflammation of interleukin-10 gene-deficient mice.9 Another study demonstrated increased small intestinal permeability in both senescence accelerated mice-prone and mdr1a-deficient mice prior to the development of colitis.10 In patients with IBD, a clinical trial with a CCR9 antagonist, which selectively blocks the migration of T cells into the small intestine, reduced disease activity in CD patients with colonic involvement.11 These data suggested that immune dysregulation in the small intestine would result in its increased epithelial permeability, which is clinically important as an etiologic event of human IBD. Another important finding of this study is that serum DAO activity was decreased in both UC and CD patients who were in remission. In this regard, we must focus on regulating mucosal permeability of the small intestine as a future therapeutic strategy for IBD patients
Additionally, known genetic susceptibility variants of IBD together with the serum level of DAO activity may allow risk assessment of disease onset.
In conclusion, measurement of serum DAO activity can be an easy and convenient modality for evaluating small intestinal permeability. Reduced serum DAO activity in patients with IBD suggests the importance of mucosal permeability of the small intestine as a pathogenic factor and its measurement together with serology, clinical factors, and genetics might be useful for predicting the disease onset of IBD. Further prospective studies with this modality are required.